RIGL biotech catalysts & pipeline

RIGEL PHARMACEUTICALS INC · Data as of 2026-10-25

Upcoming catalysts

R289 — Initial data

by year end

We are also advancing the development of R289 in our ongoing Phase 1b study in patients with R/R lower-risk MDS, and remain on track to complete enrollment in the dose expansion phase of the study, select a recommended Phase 2 dose in the second half of 2026 and share preliminary data by year end.

Source filing

GAVRETO (pralsetinib) — Conference presentation

Oct 23–Oct 27

Health-Related Quality of Life (HRQoL) Among Patients With Advanced or Metastatic RET -Fusion-Positive NSCLC Treated With Pralsetinib in ARROW Giuseppe Curigliano, MD, PhD ePoster Presentation #2808eP N/A N/A

Source filing

GAVRETO (pralsetinib) — Conference presentation

Oct 25

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced analysis of the pooled efficacy and safety data from two clinical trials of GAVRETO® (pralsetinib), ARROW (NCT03037385) and TAPISTRY (NCT04589845), in patients with rearranged during transfection ( RET ) fusion-positive solid tumors will be presented in a rapid oral session at the European Society For Medical Oncology (ESMO) Congress 2026 on Sunday, October 25, 2026.

Source filing

GAVRETO (pralsetinib) — Conference presentation

Oct 26

Pralsetinib for Advanced RET Fusion-Positive Thyroid Cancer: Results from the TAPISTRY Clinical Trial Do-Youn Oh, MD, PhD Poster Presentation #4215P Poster Display Session: Thyroid Cancer October 26, 12:00 – 12:45 pm CET

Source filing

Explore the free biotech catalyst calendar